Polartechnics shares rise after major new placement
This article was originally published in Clinica
Executive Summary
Polartechnics, an Australian company which has a cervical cancer and pre-cancer detection device in clinical trials in Europe, has raised AUS$13 million ($8.2 million) at Aus$4.40 a share from several unnamed local and overseas institutions Polartechnics said it was "an entree for major institutional investors to the company's register".